https://scholars.lib.ntu.edu.tw/handle/123456789/551136
Title: | Young chronic hepatitis b patients with nucleos(t)ide analogue-induced hepatitis b e antigen seroconversion have a higher risk of HBV reactivation | Authors: | TAI-CHUNG TSENG CHUN-JEN LIU TUNG-HUNG SU HUNG-CHIH YANG Wang C.-C CHI-LING CHEN Kuo S.F.-T CHEN-HUA LIU PEI-JER CHEN DING-SHINN CHEN JIA-HORNG KAO |
Issue Date: | 2012 | Publisher: | Oxford University Press | Journal Volume: | 206 | Journal Issue: | 10 | Start page/Pages: | 1521-1531 | Source: | Journal of Infectious Diseases | Abstract: | Background. It is unclear whether hepatitis B e antigen (HBeAg) seroconversion induced by nucleos(t)ide analogues (NUC) has a prognosis that is similar to that of spontaneous HBeAg seroconversion.Methods.A total of 148 noncirrhotic NUC-induced HBeAg seroconverters were consecutively enrolled. A historical control of 407 noncirrhotic spontaneous HBeAg seroconverters was also recruited. We compared the rates of HBeAg seroreversion and HBV reactivation between these 2 cohorts.Results.There were 1652.8 and 465.2 person-years of follow-up for spontaneous and NUC-induced HBeAg seroconverters, respectively. Compared with NUC-induced seroconverters, spontaneous seroconverters were younger when achieving HBeAg seroconversion. We thus compared these 2 cohorts according to their age at HBeAg seroconversion. In patients achieving HBeAg seroconversion before 30 years of age, NUC-induced seroconverters had a higher 2-year HBeAg seroreversion rate than spontaneous seroconverters (12.0 vs 2.9; P =. 004) and were at a higher risk of HBV reactivation (hazard ratio, 4.6; 95 confidence interval, 1.5-14.4). Using multivariate analysis, NUC-induced HBeAg seroconversion remained a risk factor of both endpoints in young HBeAg seroconverters.Conclusion.NUC-induced HBeAg seroconverters may not have durable response after stopping therapy. For patients achieving HBeAg seroconversion before 30 years of age, the risk of HBeAg seroreversion and HBV reactivation is higher in NUC-induced seroconverters than spontaneous HBeAg seroconverters. ? 2012 The Author. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84983726125&doi=10.1093%2finfdis%2fjis569&partnerID=40&md5=ee593b8731223d662097155101c53ae9 https://scholars.lib.ntu.edu.tw/handle/123456789/551136 |
ISSN: | 0022-1899 | DOI: | 10.1093/infdis/jis569 | SDG/Keyword: | adefovir; alanine aminotransferase; entecavir; hepatitis B(e) antigen; lamivudine; nucleoside analog; tenofovir; adult; age distribution; alanine aminotransferase blood level; article; cohort analysis; controlled study; drug efficacy; drug safety; female; genotype; hepatitis B; Hepatitis B virus; human; incidence; major clinical study; male; priority journal; real time polymerase chain reaction; seroconversion; treatment duration; treatment response; virus reactivation |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.